Grigolato Fulvio, Egholm Cecilie, Impellizzieri Daniela, Arosio Paolo, Boyman Onur
Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Zurich, Switzerland.
Department of Immunology, University Hospital Zurich, Zurich, Switzerland.
Allergy. 2020 Jun;75(6):1382-1393. doi: 10.1111/all.14195. Epub 2020 Feb 11.
Regulation of neutrophil chemotaxis and activation plays crucial roles in immunity, and dysregulated neutrophil responses can lead to pathology as seen in neutrophilic asthma. Neutrophil recruitment is key for initiating immune defense and inflammation, and its modulation is a promising therapeutic target. Microfluidic technology is an attractive tool for characterization of neutrophil migration. Compared to transwell assays, microfluidic approaches could offer several advantages, including precis e control of defined chemokine gradients in space and time, automated quantitative analysis of chemotaxis, and high throughput.
We established a microfluidic device for fully automated, quantitative assessment of neutrophil chemotaxis. Freshly isolated mouse neutrophils from bone marrow or human neutrophils from peripheral blood were assessed in real time using an epifluorescence microscope for their migration toward the potent chemoattractants C-X-C-motif ligand 2 (CXCL2) and CXCL8, without or with interleukin-4 (IL-4) pre-incubation.
Our microfluidic device allowed the precise and reproducible determination of the optimal CXCL2 and CXCL8 concentrations for mouse and human neutrophil chemotaxis, respectively. Furthermore, our microfluidic assay was able to measure the equilibrium and real-time dynamic effects of specific modulators of neutrophil chemotaxis. We demonstrated this concept by showing that IL-4 receptor signaling in mouse and human neutrophils inhibited their migration toward CXCL2 and CXCL8, respectively, and this inhibition was time-dependent.
Collectively, our microfluidic device shows several advantages over traditional transwell migration assays and its design is amenable to future integration into multiplexed high-throughput platforms for screening of molecules that modulate the chemotaxis of different immune cells.
中性粒细胞趋化性和激活的调节在免疫中起关键作用,中性粒细胞反应失调可导致如嗜中性粒细胞性哮喘中所见的病理状况。中性粒细胞募集是启动免疫防御和炎症的关键,其调节是一个有前景的治疗靶点。微流控技术是表征中性粒细胞迁移的一种有吸引力的工具。与Transwell分析相比,微流控方法具有多个优点,包括在空间和时间上精确控制确定的趋化因子梯度、趋化性的自动定量分析以及高通量。
我们建立了一种用于全自动、定量评估中性粒细胞趋化性的微流控装置。使用落射荧光显微镜实时评估从骨髓中新鲜分离的小鼠中性粒细胞或外周血中的人中性粒细胞向强效趋化因子C-X-C基序配体2(CXCL2)和CXCL8的迁移情况,分别在不进行或进行白细胞介素-4(IL-4)预孵育的情况下。
我们的微流控装置分别能够精确且可重复地确定小鼠和人中性粒细胞趋化性的最佳CXCL2和CXCL8浓度。此外,我们的微流控分析能够测量中性粒细胞趋化性特定调节剂的平衡和实时动态效应。我们通过证明小鼠和人中性粒细胞中的IL-4受体信号分别抑制它们向CXCL2和CXCL8的迁移,且这种抑制是时间依赖性的,来验证了这一概念。
总体而言,我们的微流控装置相对于传统的Transwell迁移分析显示出多个优点,并且其设计适合未来整合到用于筛选调节不同免疫细胞趋化性的分子的多重高通量平台中。